NCT02956317View on ClinicalTrials.gov

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Hypertrophic Scar
Interventions
DRUG

STP705

The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.

DRUG

Placebo

Normal Saline

Trial Locations (1)

90630

WCCT Global, Cypress

Sponsors

Lead Sponsor

Sirnaomics
All Listed Sponsors
lead

Sirnaomics

INDUSTRY

NCT02956317 - A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar | Biotech Hunter | Biotech Hunter